Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma

Garfall, Alfred L.; Stadtmauer, Edward A.; Hwang, Wei–Ting; Lacey, Simon F.; Melenhorst, J. Joseph; Krevvata, Maria; Carroll, Martin; Matsui, William; Wang, Qiuju; Dhodapkar, Madhav V.; Dhodapkar, Kavita M.; Das, Rituparna; Vogl, Dan T.; Weiss, Brendan M.; Cohen, Adam D.; Mangan, Patricia; Ayers, Emily C.; Nuñez-Cruz, Selene; Kulikovskaya, Irina; Davis, Megan M.; Lamontagne, Anne; Dengel, Karen; Kerr, Naseem; Young, Regina M.; Siegel, Donald L.; Levine, Bruce L.; Milone, Michael C.; Maus, Marcela V.; June, Carl H.

doi:10.1172/jci.insight.120505

Cited by 151 publications

(76 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Garfall et al evaluated CAR against CD19 (CTL019) following salvage high-dose melphalan and ASCT, in relapse and/or refractory MM patients. The study showed that 2 of 10 patients had significantly longer PFS after ASCT + CTL019 compared with prior ASCT (479 vs. 181 days; 249 vs. 127 days) [155].…”

Section: Clinical Studiesmentioning

confidence: 94%

Immunotherapy in Multiple Myeloma

Soekojo

Ooi

Mel

et al. 2020

Cells

View full text Add to dashboard Cite

show abstract

Section: Clinical Studiesmentioning

confidence: 94%

Immunotherapy in Multiple Myeloma

Soekojo

Ooi

Mel

et al. 2020

Cells

View full text Add to dashboard Cite

show abstract

“…Downregulation or loss of BCMA expression is likely an important mechanism underlying these relapses [45]. Therefore, targets other than BCMA, such as CD19 or CD138, have been investigated in CAR-T-cell studies, but yielded varying results [46,47]. Dual antigen targeting, for example by combining BCMA and CD19 CAR-T cells, is also being pursued in an attempt to improve response durability [44].…”

Section: Multiple Myelomamentioning

confidence: 99%

Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data

Roex

Feys²,

Béguin

et al. 2020

Pharmaceutics

View full text Add to dashboard Cite

Chimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy that has revolutionized the treatment of certain hematological malignancies, including B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL). The treatment is currently also being studied in other B-cell neoplasms, including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). CD19 and B-cell maturation antigen (BCMA) have been the most popular target antigens for CAR-T-cell immunotherapy of these malignancies. This review will discuss the efficacy and toxicity data from the pivotal clinical studies of CD19- and BCMA-targeted CAR-T-cell therapies in relapsed/refractory B-cell malignancies (NHL, ALL, CLL) and MM, respectively.

show abstract

“…Although myeloma is a hematological malignancy, myeloma cells do not express CD19, as they originate from plasma cells that lose CD19 when differentiating from B cells. Despite that, treatment of patients with refractory multiple myeloma using CD19-targeting CAR-T cells was attempted [340]. Two of the ten patients treated had an increased progression-free survival, and analysis of bone marrow biopsies showed an absence of myeloma cells, although, ultimately, one of them had a relapse in the form of a more aggressive and treatment-refractory myeloma.…”

Section: Engineering Of T Cells For Cancer Therapymentioning

confidence: 99%

Contribution of Macrophages and T Cells in Skeletal Metastasis

Mendoza-Reinoso

McCauley

Fournier

2020

Cancers

View full text Add to dashboard Cite

Bone is a common site for metastases with a local microenvironment that is highly conducive for tumor establishment and growth. The bone marrow is replete with myeloid and lymphoid linage cells that provide a fertile niche for metastatic cancer cells promoting their survival and growth. Here, we discuss the role of macrophages and T cells in pro- and anti-tumoral mechanisms, their interaction to support cancer cell growth, and their contribution to the development of skeletal metastases. Importantly, immunotherapeutic strategies targeting macrophages and T cells in cancer are also discussed in this review as they represent a great promise for patients suffering from incurable bone metastases.

show abstract

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma

Cited by 151 publications

References 65 publications

Immunotherapy in Multiple Myeloma

Immunotherapy in Multiple Myeloma

Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data

Contribution of Macrophages and T Cells in Skeletal Metastasis

Contact Info

Product

Resources

About